Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia

Autor: Gavin Pickett, James M. Gale, Stuart S. Winter, Jodi R. Mayfield, David R. Czuchlewski, Christian K. Nickl, Mohammad A. Vasef, Scott A. Ness, Ksenia Matlawska-Wasowska
Rok vydání: 2016
Předmět:
Oncology
medicine.medical_specialty
Ruxolitinib
Neoplasm
Residual
Adolescent
medicine.drug_class
medicine.medical_treatment
Fusion Proteins
bcr-abl
Tyrosine-kinase inhibitor
Article
Targeted therapy
03 medical and health sciences
0302 clinical medicine
Internal medicine
hemic and lymphatic diseases
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Antineoplastic Combined Chemotherapy Protocols
Nitriles
medicine
Neoplasm
Humans
Molecular Targeted Therapy
Precision Medicine
Chemotherapy
Janus kinase 2
biology
business.industry
Hematology
Janus Kinase 2
medicine.disease
Minimal residual disease
Pyrimidines
Treatment Outcome
030220 oncology & carcinogenesis
Pediatrics
Perinatology and Child Health
Immunology
Mutation
biology.protein
Pyrazoles
Female
Stem cell
business
030215 immunology
medicine.drug
Stem Cell Transplantation
Zdroj: Pediatric bloodcancer. 64(5)
ISSN: 1545-5017
Popis: A 17-year-old girl with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with persistent minimal residual disease (MRD) who underwent standard chemotherapy was found to have a BCR-ABL1-like gene expression pattern. Genome sequencing revealed a JAK2 mutation not previously described in BCP-ALL and a potential therapeutic target. Due to concern for an on-therapy relapse, the JAK2 inhibitor ruxolitinib was incorporated into a modified chemotherapy backbone to achieve complete remission prior to stem cell transplant. Treatment was well tolerated and she had undetectable MRD prior to a matched allogeneic stem cell transplant and remained in remission at day +100.
Databáze: OpenAIRE
Externí odkaz: